Objectives: Phenylketonuria (PKU) is a genetic disease with autosomal recessive inheritance. In Poland the microbiological Guthrie test for this disease was replaced by an enzymatic colorimetric test. The question is whether the colorimetric test might be used in monitoring treatment of PKU. Setting: In 80 patients with PKU on routine treatment monitoring of serum phenylalanine concentrations (SPh) was compared with phenylalanine concentrations in blood on filter paper (PhBFP). Methods: Measurements of SPh were by a fluorimetric method (McCaman and Robins), and those of PhBFP were by an enzymatic colorimetric method. Results: The regression analysis of SPh compared with PhBFP gave the equation y=0.9219x+0.2389; for the reversed ratio: it gave y=1.0220x+0.55083. The correlation was 0.97 at p<0.05. Discussion: Concentrations of SPh accepted for children with PKU are not uniform. In the Cracow centre, the range of accepted SPh concentrations are 2-6 mg/dl for children and <12 mg/dl for older patients. The concentrations of PhBFP accepted are somewhat higher than SPh, range from 4 to 10 mg/dl, and are a good indicator of an appropriate diet. Conclusions: (1) The comparison indicated that colorimetric measurements of PhBFP are effective in monitoring therapeutic PKU management. Tests can be performed more often and are more comfortable both for the patients and their parents. (2) The comparative results indicated a concentration of PhBFP ranging from 4 to 10 mg/dl to be the accepted value for children treated for PKU. P henylketonuria (PKU) is a congenital, genetic disease, which has autosomal recessive inheritance. In the classic form of PKU, the metabolic defect involves phenylalanine hydroxylase, an enzyme responsible for degrading phenylalanine to tyrosine. When this major metabolic pathway is disrupted, excessive phenylalanine accumulates in the serum, and its metabolites (phenylpyruvic, phenyl-lactic, and orthohydroxyphenylacetic acids) are excreted in the urine. Hyperphenylalaninaemia leads to brain damage, causing mental retardation. In Poland the incidence of PKU is 1:8000, whereas elsewhere it is established as 1:2000 to 1:20 000. 1 2 An early detection of phenylketonuria combined with the introduction of a therapeutic, low phenylalanine diet lead to normal development of the affected child. In newborn infants clinical manifestations are usually slight and non-specific and in some cases the condition may escape detection until the child is 1 year old. The introduction of screening programmes where the phenylalanine concentration is measured in blood on filter paper within the first few days of life has facilitated PKU detection in asymptomatic neonates. 3 Until 1998, in Poland the semiquantitative microbiological test developed by Guthrie was used; later it was replaced by an enzymatic colorimetric quantitative test. 4 5 Very precise values of phenylalanine concentrations in blood on filter paper (PhBFP) in that test have prompted the question whether it might be used in monitoring PKU treatment.
In the Cracow centre, PKU management is monitored by measuring serum phenylalanine concentrations (SPh). The present report aims to verify the validity of the quantitative method which measures PhBFP in monitoring treatment of affected children, to compare the results with SPh measurements, and to identify the range of accepted values by comparing the results obtained by the two methods.
MATERIAL AND METHODS
In the course of monitoring routine treatment of 80 patients with PKU, 480 SPh measurements were compared with 480 measurements of PhBFP (six collections per patient). All tests were performed at the Laboratory of Screening and Inborn Errors of Metabolism, University Children's Hospital of Cracow. Blood samples were drawn from the fingertip.
Measurements of SPh were made with the fluorimetric method according to McCaman and Robins. 6 The values were read on a Specol 11 fluorimeter.
Measurements of PhBFP were made by an enzymatic method. 5 Reagents for the method were supplied by IBL Gesellschaft für Immunochemie und Immunobiologie mbH, Hamburg. In Poland these reagents are routinely used in neonatal screening for PKU. The results were calculated and saved in NEOBASE software developed specially for neonatal screening purposes. 7 Blood samples were collected on Schleicher and Schleicher filter paper; each filter paper had a label with a coded number as in the procedure used in Polish neonatal screening. The drop of blood was allowed to saturate the filter paper, which was then dried at room temperature and refrigerated until dispatched to a laboratory.
RESULTS AND DISCUSSION
The results obtained in both tests are presented in figure 1 . The regression analysis of SPh compared with PhBFP gave a regression equation for the ratio of SPh to PhBFP of y=0.9219x+0.2389, whereas for the reversed ratio it was y=1.0220x+0.55083. The correlation coefficient (r) was very high, 0.97 at p<0.05. The SPh and PhBFP concentrations were also highly correlated (r=0.95). Both tests were performed as double parallel trials, with coefficient of variation not exceeding 10%.
Concentrations of SPh accepted for children under treatment by various European centres are not uniform. In Germany, for example, the range of 0.7-3.3 mg/dl is adopted for younger children and 15 mg/dl for patients aged 10-15 years. Centres in Great Britain recommend 2-6 mg/dl for preschool children, whereas in older children the value should not exceed 11.7 mg/dl. 8 In the United States, the optimum SPh concentration in patients with PKU is accepted as 3-15 mg/dl. 9 In the Cracow centre, the range of accepted values of SPh in patients with phenylketonuria that constitutes the basis of treatment monitoring follows the recommendations of the Institute of Mother and Child in Warsaw (Sendecka, Cabalska) (2-6 mg/dl for children (below 12 years old), 2-12 mg/dl (optimal <10 mg/dl) for adolescents (above 12 years old) and 2-15 mg/dl for adults). 1 When composing and monitoring the diet it should be remembered that in patients managed for phenylketonuria, phenylalanine concentrations should be somewhat higher than accepted values for the general population to prevent its deficit, as phenylalanine is an exogenous amino acid. 1 8 9 Based on the analysis carried out in our centre it is postulated that PhBFP, somewhat higher than SPh and ranging from 4 to 10 mg/dl, constitutes a good indicator of an appropriately composed diet. In younger patients-that is, below 3 years of age-the value should fall between 4 and 8 mg/dl, thus allowing for normal development of the affected child.
Measurement of PhBFP is an excellent method for neonatal screening. 5 A comparative analysis allows confirmation of its validity in monitoring of the management of phenylketonuria. Yet measurements of SPh cannot be completely abandoned, as the method is undoubtedly sensitive and in particularly difficult and unclear cases-such as differential diagnosis of hyperphenylalaninaemia and classic or atypical phenylketonuria-it is indispensable. It should also be used while composing and verifying a low phenylalanine diet in a neonate with an increased phenylalanine concentration identified in the course of screening.
The Guthrie bacterial inhibition assay is also used for monitoring dietary treatment for phenylketonuria and Rohr et al showed the usability of this method. 10 Nevertheless, in our opinion this assay is not as precise as the quantitative test and in consequence it is not as safe. Tandem mass spectrometry is also useful and Shulze et al showed that the phenylalanine/ tyrosine ratio measured by this method might be helpful in the differential diagnosis of hyperphenylalaninaemia. They also concluded that this method is an appropriate tool in neonatal screening programmes. 11 Reports on the use of tandem mass spectrometry for PKU monitoring have appeared as abstracts in conference proceedings in 2001. 12 13 It should also be remembered that on filter paper, in view of the technique used in sample collection, poor or inadequately precise spot saturation with blood may alter the quality of the result. 14 15 Nevertheless, the method is much simpler (the drawing of blood is less invasive), faster, and less expensive, and samples may be sent by post and analyzed in the course of routine screening tests. This is particularly important in older patients, whose diet does not undergo major modifications, but can be monitored with a greater frequency. Also, in children treated for phenylketonuria the NEOBASE software allows for storing patient data and all results of phenylalanine measurements. The results may be presented as a graph, which allows for follow up, starting from the original screening test through subsequent phases of diet modification until appropriate concentrations are measured and maintained. 16 We conclude that the comparison indicates that colorimetric measurements of PhBFP are effective in monitoring therapeutic management of phenylketonuria. In this method sample collection, storing, and dispatching to a laboratory are easier. Tests can be performed more often and are more comfortable both for the patients and their parents. Also the comparative results indicate that the concentration of PhBFP ranging from 4 to 10 mg/dl is the accepted value for children treated for PKU. 
